An Extension of the CONCERT Protocol (DIM18)

An Open-Label Extension of the CONCERT Protocol (DIM18) Evaluating Dimebon (Latrepirdine) in Patients With Alzheimer's Disease

An open-label extension study of the CONCERT (DIM18) protocol evaluating the safety of dimebon (latrepirdine) in subjects with With Mild-to-Moderate Alzheimer's Disease on Donepezil.

Inclusion Criteria:

• Successful completion of the 12 month DIM18 CONCERT study
• Mild-to-moderate Alzheimer's disease
• Probable AD, Diagnostic and Statistical Manual of Mental Disorders-IV-Text Revised (DSM-IV-TR)
• Mini-Mental State Exam (MMSE) score between 12 and 24, inclusive
• Stable on donepezil for at least 6 months

Exclusion Criteria:

• Other causes of dementia
• Major structural brain disease
• Unstable medical condition or significant hepatic or renal disease